The global electrophysiology market valued USD 7.1 billion in 2022 and is expected to swell at a CAGR of 9.80% over the forecast period. It is predicted that the market will reach valuation of USD 16.1 billion until 2032 from valuation of USD 7.8 billion in 2023.
The increased demand for cardiac rhythm control devices throughout the world is the reason for this growth. In order to address the complex electrical circuits of the heart, the market offers a range of diagnostic and treatment instruments, including as catheters, mapping systems, and ablation technologies.
Developments in electrophysiological technology are crucial in determining the nature of the industry. Better catheter designs, more sophisticated mapping and ablation technologies, and superior imaging modalities are the results of ongoing innovation. The electrophysiology market is expanding because to these advancements, which also enhance the precision and accuracy of diagnostic techniques and provide more affordable, minimally invasive treatment choices.
One important element impacting market dynamics is the regulatory environment around electrophysiological treatments and medical devices. Strict legal requirements guarantee the security, effectiveness, and calibre of electrophysiological technologies, which affects their acceptance, licencing, and use. In order to enter the market and foster confidence among patients, regulatory agencies, and healthcare providers, compliance with regulatory regulations is crucial.
The adoption of electrophysiological procedures is influenced by regional differences in healthcare infrastructure and economic conditions. Electrophysiology interventions are widely used, and the demand for associated technology is influenced by variations in healthcare access, reimbursement regulations, and economic situations. Companies in the market need to manoeuvre through these varied environments to guarantee that their electrophysiological solutions meet the distinct demands presented by various healthcare systems.
In the electrophysiology market, constant innovation and distinctiveness define the competitive environment. Businesses carry out R&D to launch new products with better features, such greater energy delivery for ablation, 3D mapping capabilities, and real-time navigation. This climate of competition encourages a cycle of innovation, pushing industry participants to remain at the forefront of technical developments and add to the growing scope of electrophysiological treatments.
Events pertaining to global health, like the COVID-19 pandemic, have an impact on the electrophysiology market. The demand for some electrophysiological treatments was impacted by the pandemic's interruption of elective medical operations. However, the industry recovered and expanded because healthcare systems were flexible and acknowledged the importance of electrophysiological operations.
Market innovation is facilitated by alliances and collaborations amongst research organizations, healthcare facilities, and suppliers of electrophysiological technology. These partnerships take advantage of group knowledge to tackle particular problems in cardiac electrophysiology, such customized therapy plans and the creation of cutting-edge mapping tools. The collaboration of many stakeholders quickens the speed of electrophysiological technology development and provides solutions that meet the changing demands of the healthcare sector.
Consideration of the patient-centric approach to healthcare is important in the market for electrophysiology. Technologies that put an emphasis on shorter recovery periods, procedural efficiency, and patient safety become more popular. The creation of electrophysiological solutions that improve patient outcomes, reduce radiation exposure, and improve overall patient experience is consistent with the patient-centered paradigm of contemporary healthcare.
Initiatives pertaining to education and training are crucial components of the electrophysiology industry. With the intricacy of electrophysiology treatments, healthcare personnel are being trained to employ modern technology with increasing importance. Workshops, simulation tools, and educational programmes all help to build skills and guarantee the best possible use of electrophysiological technology.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2022 | USD 7.1 Billion |
Market Size Value In 2023 | USD 7.8 Billion |
Growth Rate | 9.80% (2023-2032) |
The Electrophysiology Market Size was valued at USD 7.1 Billion in 2022 and is projected to grow from USD 7.8 Billion in 2023 to USD 16.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.80% during the forecast period (2023 - 2032). Growing demand for cardiac rhythm management devices and increasing usage of electrophysiology (EP) tests in the diagnosis and treatment of heart disorders, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Growing demand for devices for cardiac rhythm management for continuous monitoring, increasing use of these devices in non-hospital settings, and increasing use of Electrophysiology (EP) tests in the treatment and diagnosis of heart diseases, such as atrial fibrillation, are driving the industry's expansion. Due to factors including smoking, drinking too much alcohol, living sedentary lifestyles, and atrial fibrillation, millennials are more likely to experience these conditions. By 2030, the CDC projects that 12.1 million Americans will be affected by atrial fibrillation. Additionally, compared to African Americans, Europeans are more prone to atrial fibrillation. According to the European Society of Cardiology, one of the main causes of death in western countries is abrupt cardiac arrest brought on by an irregular heart rhythm. Every year, it affects about 1 in 1000 people. Cardiology specialist equipment used to diagnose and treat cardiac arrhythmias includes electrophysiology devices. Thus, the market growth is being boosted by the rising frequency of heart illnesses. Ambulatory ECG monitoring and mobile cardiac telemetry have been made easier by EP. Technology developments such cloud data storage, wireless transmission, and remote monitoring of implantable cardiac devices are anticipated to drive market expansion.
The demand for electrophysiological devices is rising as atrial fibrillation, supraventricular tachycardia, and other heart disorders become more common. For instance, the CDC estimates that 0.5% of the world's population has atrial fibrillation. Additionally, the disorder affects about 2.0% of people under the age of 65, whereas it affected about 9.0% of people over the age of 65 globally in 2019. Another dangerous disorder, ventricular tachycardia, is thought to be the cause of 300,000 fatalities annually in the United States alone. Thus, one of the main factors driving the need for these devices for diagnosis and monitoring is the rising prevalence of cardiovascular illnesses. Nearly half of American people, according to the American Heart Association, have cardiovascular disease. Additionally, atrial fibrillation (AF), which currently affects more than 16 million individuals in Asia Pacific, is expected to affect 72 million people by the year 2050, according to a report released by Biosense Webster Inc., a subsidiary of Johnson & Johnson Services. Thus, driving the Electrophysiology market revenue.
The Market segments of Electrophysiology, based on product, includes EP ablation catheters, EP laboratory devices, EP diagnostic catheters, access devices, and others. EP laboratory devices segment dominated the global market in 2022. This segment's significant market share can be attributed to a number of factors, including an increase in public-private funding for the development of novel electrophysiology recording systems, an increase in the number of RF ablation procedures, their cost-effectiveness when compared to other ablation techniques, and the expansion of their availability in key markets.
The Electrophysiology Market segmentation, based on Indication, includes atrial fibrillation (AF), atrial flutter, Wolff-Parkinson-White Syndrome (WPW), Atrioventricular Nodal Reentry Tachycardia (AVNRT), and others. Atrial fibrillation (AF) segment dominated the global market in 2022. It is the type of arrhythmia that occurs most frequently and is closely associated with a significant risk of blood clotting and stroke. In 2022, the British Heart Association predicts that 1.5 million people in the United Kingdom will have atrial fibrillation. In addition, the nation's undetected atrial fibrillation affects an estimated 270,000 people 65 and older. The significant portion of the section is caused by the disease's high prevalence.
The Market segmentation of Electrophysiology, based on end user, includes hospitals & cardiac centers, ambulatory surgery centers, and others. Hospitals & cardiac centers segment dominated the Electrophysiology Market in 2022. The majority of the market is accounted for by interventional cardiologists' use of cutting-edge cardiac rhythm management and EP technologies as well as the growing prevalence of cardiovascular disease (CVD). According to a study released in April 2018, daily short-term rhythm strip recordings revealed a rise of 13.0% in the older population admitted to hospitals for atrial fibrillation, bringing the prevalence of the condition to 46.0% overall among patients.
Figure 1: Electrophysiology Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Electrophysiology Market dominated this market in 2022 (45.80%). The high rates of heart failure, cardiac arrest, and cardiac arrhythmia are to blame for this. During the projected period, the availability of modern healthcare infrastructure and kind reimbursement policies is anticipated to fuel the region's expansion. Further, the U.S. market of electrophysiology held the largest market share, and the Canada market of electrophysiology was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ELECTROPHYSIOLOGY MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Electrophysiology market accounted for the healthy market share in 2022. The market for EP systems is expected to expand because to the quick expansion of the healthcare infrastructure and the rise in disposable income in emerging economies like Spain and Italy. The region's technological developments are also a role in the market's expansion. Further, the German market of electrophysiology held the largest market share, and the U.K market of electrophysiology was the fastest growing market in the European region
The Asia Pacific Electrophysiology market is expected to register significant growth from 2023 to 2032. The region's expansion is mostly being fueled by the high elderly population, rising risk of cardiac illnesses, and unmet clinical needs. Additionally, it is anticipated that the region's expanding healthcare spending rates, better patient awareness levels, and improved healthcare infrastructure will help manufacturers take advantage of these prospects. Moreover, China’s market of electrophysiology held the largest market share and the Indian market of electrophysiology was the fastest growing market in the Asia-Pacific region.
Electrophysiology Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of electrophysiology, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Electrophysiology industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Electrophysiology industry to benefit clients and increase the market sector. In recent years, the Electrophysiology industry has offered some of the most significant advantages to medicine. Major players in the Electrophysiology market, including Medtronic plc. (Zephyr Technology Corporation), Biotronik SE & Co. KG, MICROPORT SCIENTIFIC CORPORATION, Johnson & Johnson Services, Inc., Siemens Healthineers AG, CardioFocus, Inc., Koninklijke Philips N.V., GE Healthcare, ABBOTT LABORATORIES, and BOSTON SCIENTIFIC CORPORATION, are attempting to increase market demand by investing in research and development Indications.
A medical device business at the commercial stage is BioSig Technologies Inc. To reduce noise and artifacts from cardiac recordings during electrophysiology research and ablation, it is creating a proprietary technology platform. A medical technology business called BioSig Technologies, Inc. declared the commencement of its national commercial launch campaign in May 2022. The shift of BioSig's PURE EP System from a limited market release to a nationwide launch has been aided by a number of significant efforts. A non-invasive class II device with 510(k) clearance from the Food and Drug Administration, the PURE EP(TM) is designed to improve cardiac electrophysiology procedures' effectiveness and efficiency.
A medical technology firm called Medtronic Plc (Medtronic), originally known as Medtronic Inc., creates, develops, produces, and sells a variety of medical products. It provides products for the treatment of conditions such heart valve issues, heart failure, aortic, peripheral vascular, venous renal, and neurological problems, as well as spine and musculoskeletal issues, ear, nose, and throat conditions. Additionally, it offers biologic solutions for the dental and orthopedic markets. In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it provides its products to hospitals, third-party healthcare providers, clinics, institutions, including governmental health care programs, distributors, and group purchasing groups. The headquarters of Medtronic are in Dublin, Ireland. The Arctic Front Cardiac Cryoablation Catheter System was introduced in November 2021 by India Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc. It is the first and only cryoballoon catheter authorized by CDSCO for the treatment of atrial fibrillation (AF) in India.
Key Companies in the market of electrophysiology include
Electrophysiology Industry Developments
January 2022 The EnSite X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and throughout Europe that is designed to help doctors better treat irregular heart rhythms, also known as cardiac arrhythmias, has been approved by the United States Food and Drug Administration, according to a statement from Abbott.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)